Core Insights - CVS Health plans to expand its retail footprint in 2026 after a period of contraction, intending to open 60 stores, including 20 small pharmacy-only locations, while closing a few dozen [2][3] Group 1: Expansion Plans - CVS Health aims to open 60 new stores this year, marking a significant shift from the previous four years where it closed 1,100 locations and opened only 200 [2] - The expansion is attributed to the company's successful strategy of shutting underperforming stores and renegotiating contracts with health insurers [3] Group 2: Market Context - The retail pharmacy sector has faced challenges, including Rite Aid's bankruptcy and Walgreens being acquired by private equity, as drugstores contend with reduced drug reimbursements from health insurers and competition from discount chains and online retailers [3] - CVS has acquired 63 former Rite Aid and Bartell Drugs stores and the prescription files of 626 pharmacies across 15 states, enhancing its market position [8] Group 3: Consumer Engagement - CVS is leveraging its first-party data, which includes 90 million addressable consumers, to pursue a retail media initiative aimed at enhancing consumer engagement in-store [8] - The average dwell time at CVS pharmacies is about three minutes, presenting an opportunity for brands to engage consumers effectively [9]

Group 1: BRP Inc. (DOO) - BRP Inc. is a powersports vehicles and marine products company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 5.5% over the last 60 days [1] - BRP's shares gained 9% over the last six months, while the S&P 500 declined by 4.8% [1] - The company has a Momentum Score of A [1] Group 2: Guardian Pharmacy Services, Inc. (GRDN) - Guardian Pharmacy Services is a pharmacy service company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 10.6% over the last 60 days [2] - Guardian Pharmacy's shares gained 13.5% over the last three months, compared to a 7% decline in the S&P 500 [2] - The company possesses a Momentum Score of A [2] Group 3: Permian Resources Corporation (PR) - Permian Resources Corporation is an oil and natural gas company with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings increased by 53.1% over the last 60 days [3] - Permian Resources' shares gained 54.3% over the past three months, while the S&P 500 declined by 7% [3] - The company has a Momentum Score of A [3]

Investment Activity - Dakota Wealth Management increased its position in Walmart Inc. by 17.9% during the 4th quarter, owning 106,321 shares valued at $11,845,000 after purchasing an additional 16,125 shares [1] - Other hedge funds also adjusted their positions, with Fox Run Management purchasing $1,709,000 worth of shares, CWM LLC increasing its position by 24.2% to own 1,175,703 shares valued at $121,168,000, and Neuberger Berman Group LLC raising its holdings by 0.8% to 5,091,126 shares valued at $497,771,000 [1] - Institutional investors currently own 26.76% of Walmart's stock [1] Analyst Ratings - Evercore reissued an "outperform" rating with a price target increase to $130.00 from $125.00, while Jefferies Financial Group and Royal Bank Of Canada set a price target of $145.00 [2] - TD Cowen also reissued a "buy" rating with a price target increase to $145.00 from $136.00, and Deutsche Bank set a target of $120.00 [2] - Walmart has an average rating of "Moderate Buy" with an average price target of $135.76 according to MarketBeat.com [2] Stock Performance - Walmart shares opened at $122.89, with a market cap of $979.73 billion, a P/E ratio of 44.85, and a PEG ratio of 4.55 [3] - The stock has a 1-year low of $79.81 and a high of $134.69, with a 50-day simple moving average of $124.35 [3] Earnings Results - Walmart reported earnings of $0.74 per share for the quarter, exceeding the consensus estimate of $0.73, with revenue of $190.66 billion, surpassing analyst estimates of $188.37 billion [4] - The company's revenue increased by 5.6% compared to the same quarter last year, and it has set FY 2027 guidance at 2.750-2.850 EPS [4] Dividend Announcement - Walmart announced a quarterly dividend of $0.2475 per share, with an annualized dividend of $0.99 and a yield of 0.8% [5] - The payout ratio is currently 36.13% [5] Insider Transactions - CEO C. Douglas McMillon sold 19,416 shares at an average price of $119.17, totaling $2,313,804.72, reducing his ownership by 0.45% [6] - EVP John D. Rainey sold 20,000 shares at an average price of $122.27, totaling $2,445,400.00, representing a 3.80% decrease in ownership [8] - Corporate insiders have sold a total of 274,278 shares worth $33,825,793 over the last ninety days [8]

Core Viewpoint - Elevance Health, Inc. is considered one of the most undervalued long-term stocks to buy according to analysts, despite a recent price target reduction by Mizuho analyst Ann Hynes from $413 to $350 while maintaining a Buy rating [1]. Group 1: Analyst Insights - The reduced price target reflects the company's reaffirmed guidance amid scrutiny from the Centers for Medicare and Medicaid Services (CMS), which has raised concerns over historical data submission issues related to noncompliance in reporting diagnosis codes [2]. - Hynes emphasized that the sanctions from CMS pertain only to past processes and do not impact current risk-adjustment operations, allowing the company to maintain its 2026 outlook [4]. - The current 2026 estimates already account for any financial impacts from the CMS sanctions, leading to the reiteration of a Buy rating on the stock [4]. Group 2: Company Overview - Elevance Health operates through several segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other, with the Health Benefits segment providing a range of health plans and services [5]. - The CarelonRx segment is responsible for managing pharmacy services, while Carelon Services integrates behavioral, physical, pharmacy, and social services to offer various healthcare-related services [5].

Core Viewpoint - The article compares CVS Health and Cigna Group as potential investments for retirement portfolios, highlighting the trade-offs between stability and income versus stronger earnings quality and capital discipline. Valuation - CVS Health trades at 11.3x trailing adjusted earnings, while Cigna trades at 9.4x, making Cigna cheaper on key metrics. Cigna's 2026 adjusted EPS guidance is at least $30.25, translating to a forward multiple of approximately 9.3x, compared to CVS's 10.7x using a midpoint of $7.10 for 2026 adjusted EPS. Cigna's net income grew 73.47% year-over-year to $5.957 billion, while CVS's net income fell 62.55% to $1.728 billion due to a $5.7 billion goodwill impairment and $1.2 billion in legacy litigation charges [1]. Yield and Income - CVS offers a quarterly dividend of $0.665, annualized to $2.66, resulting in a yield of approximately 3.5%. Cigna's dividend has increased from $1.00 per quarter in 2021 to $1.56 per quarter, with a current yield of roughly 2.3% at a price of $265.88. CVS has a revenue base of $402 billion and operating cash flow of $10.639 billion for FY2025 [1]. Long-Term Track Record and Growth Trajectory - Cigna has consistently beaten adjusted EPS estimates in all four quarters of 2025, with a 17% revenue growth in its Evernorth Health Services segment and an improvement in SG&A ratio from 5.9% to 5.0%. Cigna repurchased 11.9 million shares for approximately $3.6 billion in 2025. CVS reported a 9.7% increase in same-store prescription volume and a 12.4% growth in Pharmacy & Consumer Wellness revenue to $37.66 billion, but its operating income fell 45.28% year-over-year [1]. Price Performance - Over the past year, CVS's stock is up 17.32%, while Cigna's is down 14.51%. However, over a decade, Cigna has returned 101.36%, compared to CVS's 1.84% [1]. Conclusion - For retirees prioritizing current income, CVS may be appealing due to its higher yield and growth in the pharmacy business. However, for those focused on long-term wealth accumulation, Cigna is viewed as the stronger investment due to its lower earnings multiple, consistent execution, and significant historical returns [1].

分组1 - Guardian Pharmacy Services reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, and up from $0.24 per share a year ago [1] - The company achieved a revenue of $397.62 million for the quarter, surpassing the Zacks Consensus Estimate by 2.41%, compared to $338.57 million in the same quarter last year [3] - Over the last four quarters, Guardian Pharmacy has exceeded consensus EPS estimates three times and topped revenue estimates four times [2][3] 分组2 - The stock has increased by approximately 11.8% since the beginning of the year, while the S&P 500 has declined by 0.9% [4] - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $336.07 million, and for the current fiscal year, it is $1.10 on revenues of $1.41 billion [8] - The Medical - Drugs industry, to which Guardian Pharmacy belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [9]

Core Insights - Supermarket chains are struggling against big-box retailers like Walmart, which dominates the grocery sector with a 23.6% market share and $276 billion in revenue, while Kroger holds 10.1% market share with $147 billion in revenue [1][2] Industry Challenges - Traditional grocery stores are losing market share to mass/supercenter and club stores, with the market becoming increasingly fragmented among discount grocery, dollar, drug, and specialty channels [2] - Grocery chains are facing economic challenges such as rising costs of goods and labor due to inflation, changing consumer preferences, and unmanageable lease rates [3] Store Closures - Albertsons is closing a Vons store in Escondido, California, by May 1, 2026, as part of a strategy to shut down underperforming locations, having already closed about 20 stores last year [4][5] - The Vons pharmacy will close earlier on April 16, 2026, disappointing customers who rely on its services [6] - Kroger is also closing three store locations in California and laying off 171 workers, alongside the closure of nine fulfillment centers and 60 stores over 18 months [10][11] - Ahold Delhaize USA is transitioning to a local fulfillment network by closing six centralized e-commerce fulfillment centers [12] Historical Context - Vons was founded in 1906 and grew significantly over the decades, eventually being acquired by Safeway in 1997, which was later purchased by Albertsons in 2015 [13][14]

Core Viewpoint - Kroger Co. has demonstrated strong financial performance, leading to an upgrade in stock rating and price target by Jefferies, despite slight sales misses against forecasts [2][3][6] Financial Performance - Kroger reported an adjusted profit of $1.28 per share for Q4 2025, exceeding expectations of $1.20, with GAAP earnings per share increasing by 50% to $1.35 [2][3][6] - Total sales for the full year reached $147.6 billion, reflecting a modest 0.3% increase from 2024, with same-store sales, excluding fuel, rising by 2.9% [4] - The company's operating profit surged by 36.6%, indicating robust financial health [3] Sales and Growth - Despite reporting sales of $34.7 billion, slightly below the expected $35 billion, same-store sales excluding fuel grew by 2.4% in Q4 2025 [3] - E-commerce sales saw a significant increase of 20%, contributing positively to overall performance [5][6] Cash Flow and Margins - Kroger's free cash flow nearly doubled to $3.4 billion, showcasing strong cash generation capabilities [4][6] - The company's gross margin expanded to 23.1%, driven by effective cost management strategies [5]

Core Insights - CVS Health has launched a $5 million scholarship program to support aspiring pharmacists in Louisiana, aimed at reducing financial barriers for students pursuing their Doctor of Pharmacy (PharmD) degree [1][1][1] Group 1: Scholarship Program Details - The scholarship program will provide financial assistance to students at Xavier University of Louisiana and the University of Louisiana at Monroe [1][1] - This initiative is part of CVS Health's commitment to advancing health equity and expanding access to care [1][1] - The program is designed to support students from diverse backgrounds, particularly those interested in serving areas with critical healthcare needs [1][1] Group 2: Community and Workforce Impact - The investment reflects CVS Health's commitment to strengthening the healthcare workforce and improving health outcomes in Louisiana [1][1] - The initiative aligns with Louisiana's efforts to grow a strong, homegrown healthcare workforce and create pathways for local talent [1][1] - Public-private partnerships like this are essential for ensuring the state produces skilled professionals who will remain in Louisiana [1][1] Group 3: Educational Support Initiatives - This scholarship program builds on existing CVS Health educational support initiatives, including the CVS Health/AACP Community Pharmacy Scholarship, which awards $20,000 to 21 student pharmacists nationwide [1][1] - The scholarship will be available starting the 2026-27 academic year, with more information accessible through the financial aid offices of the participating universities [1][1]

Core Insights - CVS Health Corporation reported fourth-quarter results that exceeded analyst expectations, with adjusted earnings per share of $1.09, surpassing the estimate of $1.00, and revenue of $105.7 billion, up 8.2% year over year, exceeding the forecast of $103.63 billion [1][2] Financial Performance - For full-year 2025, CVS achieved record revenue of $402.1 billion, reflecting a 7.8% year-over-year growth, while adjusted earnings per share increased by 24.5% to $6.75 [2] - The company reduced its 2026 cash flow from operations guidance to at least $9.0 billion, down from the previous target of at least $10.0 billion, while maintaining its full-year 2026 adjusted EPS guidance of $7.00 to $7.20, aligning with analyst expectations of $7.17 [2] Segment Performance - The Pharmacy & Consumer Wellness segment showed strong fourth-quarter performance, with revenue increasing by 12.4% due to higher prescription volumes and a favorable pharmacy drug mix, and same-store prescription volume rose by 9.7% on a 30-day equivalent basis [3] - The Health Services segment, which includes pharmacy benefit management, reported a 9.0% revenue increase, while the Health Care Benefits segment experienced 10.1% revenue growth but recorded an adjusted operating loss due to Medicare Part D seasonality changes under the Inflation Reduction Act [3]